Mechanistic insights into folic acid-dependent vascular protection: Dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: A novel HPLC-based fluorescent assay for DHFR activity

被引:91
作者
Gao, Ling
Chalupsky, Karel
Stefani, Enrico
Cai, Hua [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Mol Med, Cardiovasc Res Labs CVRL,Dept Anesthesiol, Los Angeles, CA 90095 USA
关键词
Folic acid (FA); Dihydrofolate reductase (DHFR); Endothelial nitric oxide synthase (eNOS); Nitric oxide (NO center dot); Angiotensin II (Ang II); Tetrahydrofolic acid (THF); CORONARY-ARTERY-DISEASE; CELLULAR REDOX STATE; B-VITAMINS; CARDIOVASCULAR-DISEASES; THERAPEUTIC TARGETS; STROKE PREVENTION; HOMOCYSTEINE; TETRAHYDROBIOPTERIN; SUPPLEMENTATION; HOMOCYSTINURIA;
D O I
10.1016/j.yjmcc.2009.07.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Folate supplementation improves endothelial function in patients with hyperhomocysteinemia. Mechanistic insights into potential benefits of folate on vascular function in general population however, remain mysterious. Expression of dihydrofolate reductase (DHFR) was markedly increased by folic acid (FA, 50 mu mol/L, 24 h) treatment in endothelial cells. Tetrahydrofolate (THF) is formed after incubation of purified DHFR or cellular extracts with 50 mu mol/L of substrate dihydrofolic acid. THF could then be detected and quantified by high performance liquid chromatography (HPLC) with a fluorescent detector (295/365 nm). Using this novel and sensitive assay, we found that DHFR activity was significantly increased by FA. Furthermore, FA improved redox status of Ang II treated cells by increasing H4B and NO center dot bioavailability while decreasing superoxide (O-2(center dot-)) production. It however failed to restore NO center dot levels in DHFR siRNA-transfected or methotrexate pre-treated cells, implicating a specific and intermediate role of DHFR. In mice orally administrated with FA (15 mg/kg/day, 16 days), endothelial upregulation of DHFR expression and activity occurred in correspondence to improved NO center dot and H4B bioavailability, and this was highly effective in reducing Ang II infusion (0.7 mg/kg/day, 14 days)-stimulated aortic O-2(center dot-) production. 5'-methyltetrahydrofolate (5'-MTHF) levels, GTPCH1 expression and activity remained unchanged in response to FA or Ang II treatment in vitro and in vivo. FA supplementation improves endothelial NO center dot bioavailability via upregulation of DHFR expression and activity, and protects endothelial cells from Ang II-provoked oxidant stress both in vitro and in vivo. These observations likely represent a novel mechanism (intermediate role of DHFR) whereby FA induces vascular protection. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:752 / 760
页数:9
相关论文
共 40 条
[1]   Assay of dihydrofolate reductase activity by monitoring tetrahydrofolate using high-performance liquid chromatography with electrochemical detection [J].
Aiso, K ;
Nozaki, T ;
Shimoda, M ;
Kokue, E .
ANALYTICAL BIOCHEMISTRY, 1999, 272 (02) :143-148
[2]   5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels - Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling [J].
Antoniades, Charalambos ;
Shirodaria, Cheerag ;
Warrick, Nicholas ;
Cai, Shijie ;
de Bono, Joseph ;
Lee, Justin ;
Leeson, Paul ;
Neubauer, Stefan ;
Ratnatunga, Chandi ;
Pillai, Ravi ;
Refsum, Helga ;
Channon, Keith M. .
CIRCULATION, 2006, 114 (11) :1193-1201
[3]   B vitamins for the prevention of vascular disease - Insufficient evidence to justify treatment [J].
Baigent, Colin ;
Clarke, Robert .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (10) :1212-1214
[4]   Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones [J].
Bauer, M ;
Suppmann, S ;
Meyer, M ;
Hesslinger, C ;
Gasser, T ;
Widmer, HR ;
Ueffing, M .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (05) :1300-1310
[5]   Effect of folic acid supplementation on risk of cardiovascular diseases - A meta-analysis of randomized controlled trials [J].
Bazzano, Lydia A. ;
Reynolds, Kristi ;
Holder, Kevin N. ;
He, Jiang .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (22) :2720-2726
[6]  
Bellamy MF, 2000, CIRCULATION, V102, pE92
[7]   Endothelial dysfunction in cardiovascular diseases - The role of oxidant stress [J].
Cai, H ;
Harrison, DG .
CIRCULATION RESEARCH, 2000, 87 (10) :840-844
[8]   The vascular NAD(P)H oxidases as therapeutic targets cardiovascular diseases [J].
Cai, H ;
Griendling, KK ;
Harrison, DG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (09) :471-478
[9]   Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase [J].
Chalupsky, K ;
Cai, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (25) :9056-9061
[10]   Improved vascular endothelial function after oral B vitamins - An effect mediated through reduced concentrations of free plasma homocysteine [J].
Chambers, JC ;
Ueland, PM ;
Obeid, OA ;
Wrigley, J ;
Refsum, H ;
Kooner, JS .
CIRCULATION, 2000, 102 (20) :2479-2483